Notícias

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

Tempus AI and Bristol Myers Squibb are expanding their collaboration to apply AI analytics and real world data to oncology and neuroscience drug development. The partnership focuses on using Tempus AI's multimodal patient data to inform clinical trial design, including programs in oncology and Alzheimer's disease. The agreement highlights growing pharmaceutical interest in AI driven tools that can address complex challenges in precision medicine research. Tempus AI, listed as NasdaqGS:TEM,...

The Dow Jones Industrial Average, Nasdaq Composite and S&P 500 Index were down in late-morning tradi

Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.

A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.

Shares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

Bristol-Myers Squibb (BMY) has just signed a collaboration and licensing agreement with Hengrui Pharma covering 13 early stage oncology, hematology and immunology programs, a large commitment that could reshape its future pipeline. See our latest analysis for Bristol-Myers Squibb. At a share price of $56.77, Bristol-Myers Squibb has a 1-year total shareholder return of 30.12%, while the year to date share price return of 6.19% and recent 90 day share price weakness suggest momentum has...

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

Bristol-Myers Squibb has had an impressive run over the past six months as its shares have beaten the S&P 500 by 5.7%. The stock now trades at $55.77, marking a 13.6% gain. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.

Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.

PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.

RDY stock down 5% on missing fiscal fourth-quarter 2026 earnings and revenue estimates as North America generics sales slumped.

Bristol-Myers will pay Hengrui up to $950 million by 2028 for 13 early-stage programs.

The two companies will trade the greater Chinese and US rights to certain programmes under their jurisdiction, while working in tandem to progress these assets.

The agreement covers 13 early-stage programs in oncology, hematology, and immunology, with $600 million due upfront

Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.

Bristol-Myers Squibb (NYSE:BMY) has entered a multi billion dollar global drug development alliance with Hengrui Pharma. The collaboration covers 13 early stage oncology, hematology, and immunology programs under a broad licensing and co development framework. The agreement includes upfront and milestone payments and expands Bristol-Myers Squibb's global R&D reach and early pipeline coverage. Bristol-Myers Squibb, trading at $55.67, is adding this wide ranging partnership on top of an...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S. and Europe-based counterparts.

Bristol-Myers Squibb (BMY) and Hengrui Pharma signed collaboration and licensing agreements to devel

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.

This may be an excellent deal for those focused on the long game.

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen. On April 30, 2026, Reuters reported that Bristol-Myers Squibb Company (NYSE:BMY) announced first-quarter adjusted earnings of $1.58 per share, which came in above analysts’ average estimate of $1.42. The revenue of $11.49 billion also exceeded […]

The average American household spends about $519 a month on groceries, based on the latest BLS Consumer Expenditure Survey figure of $6,224 a year, and grocery prices are still rising: food-at-home prices were up 1.9% year over year as of March 2026. Add about $280 for utilities and roughly $100 for phone and internet, plus ... A $185,000 Portfolio That Covers Your Groceries, Utilities, and Phone Bill Every Month

Bristol Myers Squibb (NYSE:BMY) used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independe

European Commission approves Bristol Myers Squibb's Sotyktu (deucravacitinib) as the first TYK2 inhibitor for active psoriatic arthritis in adults. Approval covers patients who have had an inadequate response or intolerance to one or more conventional synthetic disease modifying antirheumatic drugs. Decision is based on Phase 3 clinical trial data and extends Sotyktu beyond its existing use in dermatology. For investors watching NYSE:BMY, this decision adds a fresh development within the...

Xenon Pharmaceuticals (NASDAQ:XENE) said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first q